Trials / Active Not Recruiting
Active Not RecruitingNCT06243679
The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC
The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC: a Prospective Real-World Study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Xiangya Hospital of Central South University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, observational, multicenter real-world study aiming to investigate the efficacy and safety of NSCLC patients with or without adjuvant immunotherapy who have achieved pathologic complete remission after neoadjuvant immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Immunotherapy | Monotherapy with PD-1 inhibitors, up to 1 year. |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2027-09-01
- Completion
- 2027-12-01
- First posted
- 2024-02-06
- Last updated
- 2024-12-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06243679. Inclusion in this directory is not an endorsement.